



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Draghia-Akli, Ruxandra, et al.


Serial No.: 10/798,896

Filed: 03/11/2004

For: INSULIN-LIKE GROWTH FACTOR (IGF-I) PLASMID-MEDIATED  
SUPPLEMENTATION FOR THERAPEUTIC APPLICATIONS

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:



FIRST SUPPLEMENTAL TRANSMITTAL OF INFORMATION  
DISCLOSURE STATEMENT

Applicant certifies under 37 C.F.R. § 1.97(d)(2)(1) that the references contained in the information disclosure statement filed herewith were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. Three of the five references cited by the European Patent Office have been included in the original Information Disclosure Statement filed on May 19, 2004, copies of which are, therefore, not submitted herewith.

Respectfully submitted,  
JACKSON WALKER L.L.P.

  
T. Ling Chwang  
Registration No. 33,590

October 8, 2004  
Dated:

JACKSON WALKER L.L.P.  
2435 North Central Expressway, Suite 600  
Richardson, Texas 75080  
Tel: (972) 744-2919  
Fax: (972) 744-2909

Sheet	1	of	2 Sheets
-------	---	----	----------


Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	AVSI-0034 (108328.00172)

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



AVSI-00034 (108328.00172)

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2 Sheets

### Complete if Known

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	AVSI-0034 (108328.00172)

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	RABINOVSKY E. D., Draghia-Akli R., Insulin-Like Growth Factor I Plasmid Therapy Promotes in vivo Angiogenesis. Molecular Therapy Vol 9, No. 1, p 46-54 (2004).	
	3	International Search Report, International Application No. PCT/US 04/007295, August 8, 2004	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.